Antimicrobial Agents and Chemotherapy · 2004 · 142 citations · 25 references
MedicineInfectious DiseasesPharmacologyMolecular PharmacologyMolecular VirologyVirologyAntiviral AgentsAntiviral PharmacologyAntiviral TherapyViral InfectionsViral ReplicationAntiviral Mechanisms Of ActionAntiviral TherapeuticsViral Replication ControlViral Replication InhibitionViral Replication Inhibitors
Human cytomegalovirus (HCMV) is a major human pathogen frequently associated with life-threatening disease in immunosuppressed patients and newborns. The HCMV UL97-encoded protein kinase (pUL97) represents an important determinant of viral replication. Recent studies demonstrated that pUL97-specific kinase inhibitors are powerful tools for the control of HCMV replication. We present evidence that three related quinazoline compounds are potent inhibitors of the pUL97 kinase activity and block in vitro substrate phosphorylation, with 50% inhibitory concentrations (IC(50)s) between 30 and 170 nM. Replication of HCMV in primary human fibroblasts was suppressed with a high efficiency. The IC(50)s of these three quinazoline compounds (2.4 +/- 0.4, 3.4 +/- 0.6, and 3.9 +/- 1.1 microM, respectively) were in the range of the IC(50) of ganciclovir (1.2 +/- 0.2 microM), as determined by the HCMV green fluorescent protein-based antiviral assay. Importantly, the quinazolines were demonstrated to have strong inhibitory effects against clinical HCMV isolates, including ganciclovir- and cidofovir-resistant virus variants. Moreover, in contrast to ganciclovir, the formation of resistance to the quinazolines was not observed. The mechanisms of action of these compounds were confirmed by kinetic analyses with infected cells. Quinazolines specifically inhibited viral early-late protein synthesis but had no effects at other stages of the replication cycle, such as viral entry, consistent with a blockage of the pUL97 function. In contrast to epithelial growth factor receptor inhibitors, quinazolines affected HCMV replication even when they were added hours after virus adsorption. Thus, our findings indicate that quinazolines are highly efficient inhibitors of HCMV replication in vitro by targeting pUL97 protein kinase activity.
25
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets
Martin H. Cohen, Grant A. Williams, Rajeshwari Sridhara et al. · The Oncologist · 2003 · 577 citations · Full text
Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus
Xin Wang, Shu-Mei Huong, Marie L. Chiu et al. · Nature · 2003 · 422 citations
Eva Maria Borst, Gabriele Hahn, Ulrich H. Koszinowski et al. · Journal of Virology · 1999 · 388 citations · Full text
Karen K. Biron, Stanley C. Chamberlain, Steven S. Good et al. · Antimicrobial Agents and Chemotherapy · 2002 · 364 citations · Full text